Iterum Therapeutics (ITRM)
(Real Time Quote from BATS)
$1.21 USD
-0.01 (-0.82%)
Updated Jun 27, 2024 03:51 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Brokerage Reports
Iterum Therapeutics PLC [ITRM]
Reports for Purchase
Showing records 21 - 40 ( 71 total )
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
IDWeek 2021: Poster Presentation Highlights Within Our Antibiotics Coverage Space
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Type A Meeting Offers Path Forward for Sulopenem via New Phase 3 Study; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
2Q21 Recap: Type A Meeting With FDA in Coming Weeks to Determine Sulopenem''s Future; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
CRL Requests a New Sulopenem Trial; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
FDA Flags Deficiencies in Sulopenum NDA; Approval on July 25 PDUFA at Risk; Maintain Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Avoiding the Distracting Whipsaw of Agency Communications, We Remain Focused on July 25 PDUFA; 1Q Recap; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
4Q Recap: A Clear Line of Sight to a Significant Opportunity in uUTI; Upgrading to Buy, $2.50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
Sulopenem NDA for uUTI Accepted With July 25 PDUFA Date; Awaiting Commercial Plan to Solidify; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Iterum Therapeutics PLC
Industry: Medical - Drugs
CSO Resigns, Added to the Board; Potential Sulopenem NDA Acceptance Next Month; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E